聚合搜Scholar - 壹搜网为您找到"
WWDC26:2026 年 6 月 8 日至 12 日 (太平洋时间)
"相关结果 10条Oral epithelial dysplasia (OED) often precedes oral squamous cell carcinoma (OSCC). The aim was to elucidate the risk and time of malignant transformation (MT) of OED.
www.ncbi.nlm.nih.govRetrospective Analysis.
www.ncbi.nlm.nih.govZoonotic malaria caused by infection with the monkey parasite
www.ncbi.nlm.nih.govDespite global progress in reducing HIV-related morbidity and mortality, preventable deaths persist, particularly in sub-Saharan Africa. Ethiopia has achieved near-universal antiretroviral therapy (ART) coverage, yet survival outcomes and predictors of mortality in the era of 'test and treat' remain underexplored. This study examined survival rates and predictors of mortality among people living with HIV (PLHIV) on ART in Ethiopia between 2016 and 2023.
www.ncbi.nlm.nih.govAmbulatory care sensitive conditions (ACSC) are health conditions that can be adequately managed in the outpatient setting. Timely treatment and interventions may avoid the need for hospitalisation and emergency department visits.
www.ncbi.nlm.nih.govMental nerve skeletonization is commonly required during intraoral open reduction and internal fixation (ORIF) of mandibular parasymphysis and body fractures, yet objective, time-based data on functional sensory recovery (FSR) remain limited.
www.ncbi.nlm.nih.govTo evaluate quality of life (QoL) outcomes following varicose vein surgery and identify predictors of postoperative QoL to inform patient counselling and clinical management.
www.ncbi.nlm.nih.govSubcutaneous (SC) infliximab (IFX) has recently been approved for the treatment of chronic inflammatory rheumatic diseases (CIR), largely based on the results of large randomized trials in rheumatoid arthritis. However, real-world evidence remains limited and is mainly retrospective. The aim of this study was to evaluate the safety and effectiveness of SC IFX following a non-medical switch from intravenous (IV) IFX in patients with CIR.
www.ncbi.nlm.nih.govPrior data suggest that patients with intrahepatic cholangiocarcinoma (iCCA) have a better prognosis compared to other biliary tract cancers (BTC). However, granularity on outcomes for advanced extrahepatic cholangiocarcinoma (eCCA) (including distal- (dCCA) and perihilar cholangiocarcinoma (pCCA)) and gallbladder cancer (GBC) is lacking. With targeted therapies being developed for these subgroups, benchmark data is of value to understand the natural history and inform future trial design.
www.ncbi.nlm.nih.govAccurate estimation of methane (CH
www.ncbi.nlm.nih.gov